Agomab appoints board member, chief development officer

Agomab Therapeutics SA
Appointee name
Angelika Jahreis and Andrea Sáez


Angelika Jahreis, a senior executive at Novartis, has been appointed to the board of Agomab Therapeutics SA as an independent non-executive director and Andrea Sáez will join Agomab’s executive leadership team as chief development officer. Dr Jahreis is currently senior vice president, development unit head of immunology at Novartis, and has over 20 years experience in drug development at Novartis, Gilead, Genentech and Amgen. She holds an MD and PhD from the University of Freiburg, Germany.

Dr Sáez, formerly at Origo Biopharma, became head of portfolio at Agomab following the acquisition of Origo by Agomab in late 2021. At Agomab she led the development of AGMB-129, for the potential treatment of fibrostenosing Crohn’s disease into Phase 2 trials. The drug received a fast track designation from the US Food and Drug Administration in October 2023. Dr Sáez holds a PhD in immunology from the Pompeu Fabra University, Spain.

Agomab announced the appointments on November 29, 2023.

Copyright 2024 Evernow Publishing Ltd.